Replies to post #1115 on Armata Pharmaceuticals, Inc. (ARMP)

[longmike2]

lets see.....

the filing
SAN DIEGO--(BUSINESS WIRE)-- AmpliPhi Biosciences Corporation (NYSE American: APHB), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced the pricing of a public offering of 4,000,000 shares of its common stock, offered at a price to the public of $1.00 per share, for gross proceeds of $4.0 million, before deducting placement agent fees and offering expenses payable by AmpliPhi. The offering is expected to close on or about January 12, 2018, subject to customary closing conditions.

H.C. Wainwright & Co., LLC is acting as the placement agent for the offering.

AmpliPhi intends to use the net proceeds from the offering for general corporate purposes, including manufacturing expenses, clinical trial expenses, research and development expenses and general and administrative expenses.

The securities described above are being offered by AmpliPhi pursuant to a shelf registration statement (File No. 333-210974) previously filed and declared effective by the Securities and Exchange Commission (“SEC”) on May 13, 2016. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and a final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC. When available, electronic copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained from H.C. Wainwright & Co., LLC, 430 Park Avenue, New York, NY 10022, by e-mailing [e-mail] or by calling [phone], or by accessing the SEC’s website at www.sec.gov.

Latest Filing

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Mary Beth Breslin, Legal Branch Chief, Office of Healthcare & Insurance



Re: AmpliPhi Biosciences Corporation

Registration Statement on Form S-1 (File No. 333-222059)

CIK No. 0000921114

Filed December 14, 2017

Application for Withdrawal



Ladies and Gentlemen:



AmpliPhi Biosciences Corporation (the “ Registrant ”) hereby respectfully requests that the Securities and Exchange Commission (the “ Commission ”) consent to the withdrawal of its Registration Statement (File No. 333-222059) on Form S-1, together with all exhibits thereto (collectively, the “ Registration Statement ”). The Registration Statement was initially filed with the Commission on December 14, 2017.



The Registrant confirms that no securities have been issued or sold under the Registration Statement. The Registration Statement has not been declared effective by the Commission. The Registrant has determined at this time not to proceed with the offering and requests that the Commission consent to this application on the grounds that withdrawal of the Registration Statement is consistent with the public interest and the protection of investors, as contemplated by paragraph (a) of Rule 477 of the Securities Act of 1933, as amended (the “ Securities Act ”).



It is the Registrant’s understanding that this application for withdrawal of the Registration Statement will be deemed granted as of the date that it is filed with the Commission unless, within fifteen days after such date, the Registrant receives notice from the Commission that this application will not be granted.



The Registrant requests that, in accordance with Rule 457(p) under the Securities Act, all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use.

looks like 2 different filing number and 2 different dates. how confusing was that!!! lets look back to Dec 14th and see what that filing was!


GOT IT! so they cancelled the WARRANTS.... and instead sold to Investor 4 million shares at $1.00

Shares of Common Stock
Warrants to Purchase ???? Shares of Common Stock

We are offering up to ???? shares of our common stock and warrants to purchase an aggregate of ???? shares of our common stock (and the shares of common stock that are issuable from time to time upon exercise of the warrants). Each share of common stock is being sold together with a warrant to purchase ???? share of our common stock, at an exercise price of? $????per share. The warrants will be exercisable immediately and will expire ???? years from the date of issuance. The shares of common stock and the accompanying warrants can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance. Our common stock is listed on the NYSE American under the symbol “APHB.” On December 13, 2017, the last reported sale price of our common stock on the NYSE American was $1.01 per share. The public offering price per share of common stock and accompanying warrant will be determined by us at the time of pricing, may be at a discount to the current market price, and the recent market price used throughout this prospectus may not be indicative of the final offering price. There is no established public trading market for the warrants, and we do not expect a market to develop. In addition, we do not intend to apply for a listing of the warrants on any national securities exchange.

All sales will be evidenced by separate subscription agreements between us and the investors in this offering. ???? will serve as escrow agent for the deposit and disbursement of the purchase price of the shares and warrants sold in this offering. See “Plan of Distribution” on page 21 of this prospectus for more information regarding these arrangements.

We are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings.


ahhh and then came this!!

Ampliphi Biosciences (NYSEAMERICAN:APHB) had its target price hoisted by HC Wainwright from $5.00 to $6.00 in a research report issued to clients and investors on Wednesday, January 17th, MarketBeat reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 455.56% from the company’s current price.

Ampliphi Biosciences (APHB) opened at $1.08 on Wednesday. The firm has a market capitalization of $10.16, a P/E ratio of -0.11 and a beta of 2.93. Ampliphi Biosciences has a 1 year low of $0.67 and a 1 year high of $6.80.


So they got the money and are continuing daily operations....sole investor took the shares for a no sell agreement with a TIMEFRAME IM SURE